Jan 27, 2023 Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules
Nov 10, 2022 Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Nov 08, 2022 Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders
Sep 22, 2022 Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA